Last updated: July 10, 2026

Application No. 19/378,410

Untitled Application

Unknown

Filed

Priority

Nov 05, 2024 — provisional 63/716,349 +2 more

Examiner

KONOPELSKI SNAVEL, SARA ELIZABETH

Art Unit

Tech Center

Novo Nordisk A/S

Assignee

Novo Nordisk Inc.

OA Round

2 (Non-Final)

This examiner grants 25% of cases after interview

— +31.1% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 24 resolved cases, 2023–2026

Examiner Intelligence

KONOPELSKI SNAVEL, SARA ELIZABETH View full profile →

Grants only 25% of cases

Career Allowance Rate

6 granted / 24 resolved

-35.0% vs TC avg

Strong +31% interview lift

Without

With

+31.1%

Interview Lift

resolved cases with interview

Typical timeline

3y 7m

Avg Prosecution

46 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§101

1.4%

-38.6% vs TC avg

§103

30.3%

-9.7% vs TC avg

§102

11.0%

-29.0% vs TC avg

§112

4.1%

-35.9% vs TC avg

Black line = Tech Center average estimate • Based on career data from 24 resolved cases

Prosecution Timeline

Jan 15, 2026

Non-Final Rejection mailed

May 15, 2026

Response Filed

Jul 07, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/617,269

Patent 12577278

KRAS G12V Mutant Binds to JAK1, Inhibitors, Pharmaceutical Compositions, and Methods Related Thereto

4y 3m to grant Granted Mar 17, 2026

18/385,640

Patent 12486303

NOVEL USE OF PEPTIDE FOR INHIBITING FUNCTIONS AND EXPRESSIONS OF MULTIPLE DISEASE BIOMARKERS

2y 1m to grant Granted Dec 02, 2025

17/741,590

Patent 12441769

POLYPEPTIDE, PHOTORESIST COMPOSITION INCLUDING THE SAME, AND METHOD OF FORMING PATTERN USING THE SAME

3y 5m to grant Granted Oct 14, 2025

Study what changed to get past this examiner. Based on 3 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3

Expected OA Rounds

25%

Grant Probability

56%

With Interview (+31.1%)

3y 7m

Median Time to Grant

Moderate

PTA Risk

Based on 24 resolved cases by this examiner. Grant probability derived from career allowance rate.